Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

FTC approves modifications to Boston Scientific divestiture agreement

Published 02/18/2022, 01:14 PM
Updated 02/18/2022, 01:15 PM
© Reuters. FILE PHOTO: Federal Trade Commission seal is seen at a news conference at FTC Headquarters in Washington, U.S., July 24, 2019. REUTERS/Yuri Gripas

(Reuters) - The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific (NYSE:BSX) Corp’s divestiture agreements.

"The FTC approved these agreements and incorporated them into its order as part of a consent agreement it required in 2019, when Boston Scientific acquired medical equipment and pharmaceutical supplier BTG plc," the FTC said in a statement https:// on Friday.

As a condition of Boston Scientific's acquisition of BTG, the FTC required it to divest to Varian Medical Systems (NYSE:VAR) its Drug Eluding Beads (DEBs) and bland beads business, the FTC said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.